Dr. Paul Thielking reports

CEDAR CLINICAL RESEARCH SELECTED AS CLINICAL RESEARCH SITE FOR BECKLEY PSYTECH'S PHASE 2B STUDY

Numinus Wellness Inc.'s research site, Cedar Clinical Research (CCR), has been chosen as one of multiple sites for Beckley Psytech's cutting-edge phase 2b clinical trial for treatment-resistant depression (TRD).

The study aims to evaluate the efficacy and safety of different doses of Beckley Psytech's proprietary intranasal formulation of synthetic 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) -- known as BPL-003 -- as a potential therapy for TRD. It follows Beckley Psytech's receipt of the U.S. Food and Drug Administration's (FDA) first-ever investigational new drug (IND) approval for a phase 2b study of a short-acting psychedelic compound in February this year. CCR's selection as a clinical research site for this trial further establishes it as a leader in psychedelic clinical research and builds upon its commitment to forging collaborations that explore new mental health solutions.

"We are excited to be supporting Beckley Psytech in their clinical trial endeavours. Such partnerships are not just a reflection of CCR's dedication to advancing the frontiers of mental health research; they also spotlight our capabilities and the world-class infrastructure that positions us as a sought-after clinical research hub," stated Dr. Paul Thielking, chief science officer at Numinus. "Our collaboration with Beckley Psytech underscores a shared vision and commitment to bringing the highest research standards to psychedelic clinical trials. With each groundbreaking project, we further cement our global standing, always driven by innovation, integrity and excellence."

Numinus and CCR's collaboration with Beckley Psytech reflects a unified drive for innovation in psychedelic-assisted therapies. As leaders in mental health solutions, they eagerly anticipate the transformative insights this phase 2b trial will offer to the broader medical community.

Numinus and CCR remain at the forefront of advancing psychedelic-assisted therapies, underscoring a deep-seated commitment to research that paves the way for comprehensive healing.

About Numinus Wellness Inc.

Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model -- including psychedelic research and clinic care -- is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. Numinus is leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

We seek Safe Harbor.